Medicenna Therapeutics Names Dr. Nageatte Ibrahim as Chief Medical Officer

Medicenna Therapeutics Corp. (MDNAF.PK) announced on Thursday the appointment of Dr. Nageatte Ibrahim as the company's new Chief Medical Officer. Dr. Ibrahim joins the firm with a deep background in oncology, having previously served as the Chief Medical Officer of Oncology at Innovent Biologics USA. During her tenure at Innovent Biologics, Dr. Ibrahim was responsible for establishing and leading a global clinical development organization. She played a pivotal role in expanding the company's operational presence and strategic footprint within the United States market. In her new capacity at Medicenna, Dr. Ibrahim will focus on advancing the company's IL-2 superagonist programs, specifically MDNA11 and MDNA113. She highlighted the potential of bizaxofusp (MDNA55), noting its compelling evidence of efficacy in treating glioblastoma, a challenging form of cancer with significant unmet medical needs. Following the announcement, shares of MDNAF closed at $0.46 on the OTC Markets, marking a 4.31 percent increase. The appointment is viewed as a strategic step toward accelerating the clinical development and regulatory pathway for the company's specialized cancer therapies.